AUS
NZ
UK
CA
USA
IND
Highlights
- Orthocell (OCC) submits FDA application for Remplir™, targeting the expansive US nerve repair market.
- Successful study positions Remplir™ as a safe and effective solution for peripheral nerve repair.
- Company prepares for US launch, supported by a robust balance sheet and strategic planning.
Orthocell (ASX:OCC) has submitted a pivotal 510(k) regulatory application to the United States Food and Drug Administration (FDA) for its nerve repair product, Remplir™, setting its sights on the lucrative US$1.6 billion nerve repair market. The submission follows a successful regulatory study that met all key benchmarks, confirming Remplir™ as a safe and effective option for surgical peripheral nerve repair. This development marks a major milestone for Orthocell, as it seeks to introduce its innovative product to the largest healthcare market globally.
The FDA submission reflects Orthocell’s comprehensive preparation, bolstered by pre-submission meetings and strong regulatory data. The pivotal study highlighted Remplir’s capabilities, showcasing outcomes comparable to existing FDA-cleared devices. With endorsements from surgeons in regions where the product is already approved, including Australia, New Zealand, and Singapore, Orthocell aims to leverage its proven track record in advanced nerve repair technology.
Orthocell’s leadership is optimistic about the future. CEO Paul Anderson emphasized the significance of this step, noting the company’s readiness to drive Remplir’s success in the US market. With a well-prepared sales and medical affairs team, Orthocell is strategically positioned for the anticipated FDA clearance, expected by early 2025, following the standard review period.
Beyond the US, Orthocell is actively expanding its regulatory footprint. The company plans to explore approvals in additional markets, including Canada, Europe, the UK, and ASEAN countries. Supported by a robust financial standing, with A$33 million in cash reserves as of November 2024, Orthocell is poised for significant growth and market penetration.
The US nerve repair market represents a significant opportunity for Orthocell, given its estimated value of more than US$1.6 billion annually. Orthocell (OCC) is set to capitalize on this growing demand with its innovative solutions, aiming to redefine the field of nerve repair with the launch of Remplir™. The company’s strategic focus on innovation, regulatory compliance, and market readiness positions it as a leader in delivering advanced healthcare solutions.
